309 related articles for article (PubMed ID: 32169088)
1. Radiation-induced lymphopenia correlates with survival in nasopharyngeal carcinoma: impact of treatment modality and the baseline lymphocyte count.
Xie X; Gong S; Jin H; Yang P; Xu T; Cai Y; Guo C; Zhang R; Lou F; Yang W; Wang H
Radiat Oncol; 2020 Mar; 15(1):65. PubMed ID: 32169088
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Value of Treatment-Related Lymphopenia in Nasopharyngeal Carcinoma Patients.
Liu LT; Chen QY; Tang LQ; Guo SS; Guo L; Mo HY; Chen MY; Zhao C; Guo X; Qian CN; Zeng MS; Bei JX; Tan J; Chen S; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Cancer Res Treat; 2018 Jan; 50(1):19-29. PubMed ID: 28392551
[TBL] [Abstract][Full Text] [Related]
3. Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
Davuluri R; Jiang W; Fang P; Xu C; Komaki R; Gomez DR; Welsh J; Cox JD; Crane CH; Hsu CC; Lin SH
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):128-135. PubMed ID: 28816138
[TBL] [Abstract][Full Text] [Related]
4. Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature.
Wang S; Li S; Shen L
Curr Probl Cancer; 2018; 42(3):302-318. PubMed ID: 29759802
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
[TBL] [Abstract][Full Text] [Related]
7. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of intensity-modulated radiation therapy versus 2D-RT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis.
Du T; Xiao J; Qiu Z; Wu K
PLoS One; 2019; 14(7):e0219611. PubMed ID: 31291379
[TBL] [Abstract][Full Text] [Related]
9. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
[TBL] [Abstract][Full Text] [Related]
10. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results.
Hu J; Bao C; Gao J; Guan X; Hu W; Yang J; Hu C; Kong L; Lu JJ
Cancer; 2018 Jun; 124(11):2427-2437. PubMed ID: 29579324
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Analysis of the Survival Benefit of Induction Chemotherapy in Stage IVa-b Nasopharyngeal Carcinoma.
Lan XW; Zou XB; Xiao Y; Tang J; OuYang PY; Su Z; Xie FY
PLoS One; 2016; 11(8):e0160758. PubMed ID: 27509025
[TBL] [Abstract][Full Text] [Related]
12. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Analysis of Treatment Management and Survival Outcomes in Nasopharyngeal Carcinoma.
Goshtasbi K; Lehrich BM; Birkenbeuel JL; Abiri A; Harris JP; Kuan EC
Otolaryngol Head Neck Surg; 2021 Jul; 165(1):93-103. PubMed ID: 33231508
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of concurrent chemoradiotherapy in subgroups of stage III nasopharyngeal carcinoma: an analysis based on 10-year follow-up.
Wang L; Wu Z; Cheng W; Xie D; Lin F; Xia L; Su Y
Radiat Oncol; 2021 Nov; 16(1):215. PubMed ID: 34742304
[TBL] [Abstract][Full Text] [Related]
15. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
Luo Y; Qin Y; Lang J
Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
[TBL] [Abstract][Full Text] [Related]
16. Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study.
Liu F; Luo T; Jin T; Zhang J; Xiang Z; Yan R; Xie L; Wu X; Zhang H; Wang F; Li P; Liu L
BMC Cancer; 2019 Jun; 19(1):554. PubMed ID: 31176358
[TBL] [Abstract][Full Text] [Related]
17. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.
Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W
J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113
[TBL] [Abstract][Full Text] [Related]
18. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
[TBL] [Abstract][Full Text] [Related]
19. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
[TBL] [Abstract][Full Text] [Related]
20. Intensity-modulated radiation therapy achieves better local control compared to three-dimensional conformal radiation therapy for T4-stage nasopharyngeal carcinoma.
Chen JL; Huang YS; Kuo SH; Hong RL; Ko JY; Lou PJ; Wang CW
Oncotarget; 2017 Feb; 8(8):14068-14077. PubMed ID: 27764778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
